MX2019014760A - Vectores de aav autoregulables para la expresión segura de mecp2 en el síndrome de rett. - Google Patents
Vectores de aav autoregulables para la expresión segura de mecp2 en el síndrome de rett.Info
- Publication number
- MX2019014760A MX2019014760A MX2019014760A MX2019014760A MX2019014760A MX 2019014760 A MX2019014760 A MX 2019014760A MX 2019014760 A MX2019014760 A MX 2019014760A MX 2019014760 A MX2019014760 A MX 2019014760A MX 2019014760 A MX2019014760 A MX 2019014760A
- Authority
- MX
- Mexico
- Prior art keywords
- mecp2
- rett syndrome
- self
- aav vectors
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/10—Production naturally occurring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762516060P | 2017-06-06 | 2017-06-06 | |
| PCT/US2018/036200 WO2018226785A1 (en) | 2017-06-06 | 2018-06-06 | Self-regulating aav vectors for safe expression of mecp2 in rett syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019014760A true MX2019014760A (es) | 2020-08-03 |
Family
ID=64567243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014760A MX2019014760A (es) | 2017-06-06 | 2018-06-06 | Vectores de aav autoregulables para la expresión segura de mecp2 en el síndrome de rett. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11680275B2 (enExample) |
| EP (1) | EP3635122A4 (enExample) |
| JP (2) | JP2020522269A (enExample) |
| KR (1) | KR20200015701A (enExample) |
| CN (1) | CN111065742A (enExample) |
| AU (1) | AU2018281145A1 (enExample) |
| BR (1) | BR112019025732A2 (enExample) |
| CA (1) | CA3066623A1 (enExample) |
| CL (1) | CL2019003582A1 (enExample) |
| CO (1) | CO2019014840A2 (enExample) |
| EA (1) | EA201992882A1 (enExample) |
| IL (1) | IL271170A (enExample) |
| MX (1) | MX2019014760A (enExample) |
| SG (1) | SG11201911737PA (enExample) |
| WO (1) | WO2018226785A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10370432B2 (en) | 2014-10-03 | 2019-08-06 | University Of Massachusetts | Heterologous targeting peptide grafted AAVS |
| US10584321B2 (en) | 2015-02-13 | 2020-03-10 | University Of Massachusetts | Compositions and methods for transient delivery of nucleases |
| IL322146A (en) | 2016-11-17 | 2025-09-01 | Nationwide Childrens Hospital Inc | Intrathecal administration of adenovirus encoding methyl-CpG-binding protein 2 |
| ES2944358T3 (es) | 2017-01-30 | 2023-06-20 | Brainvectis | Vector de expresión para la colesterol 24-hidrolasa en terapia de ataxias espinocerebelosas de repetición de poliglutamina |
| WO2019195444A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Antibody-evading virus vectors |
| JP7425738B2 (ja) | 2018-04-03 | 2024-01-31 | ギンコ バイオワークス インコーポレイテッド | 眼組織を標的とするウイルスベクター |
| CN112272672A (zh) | 2018-04-03 | 2021-01-26 | 斯特里迪比奥公司 | 抗体逃避性病毒载体 |
| EP3861010A1 (en) | 2018-10-02 | 2021-08-11 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
| CA3133453A1 (en) | 2019-03-21 | 2020-09-24 | Daniel Mccoy | Recombinant adeno-associated virus vectors |
| CN114026236A (zh) * | 2019-04-24 | 2022-02-08 | 宾夕法尼亚州大学信托人 | 可用于治疗雷特综合征的组合物 |
| JP7624410B2 (ja) * | 2019-05-21 | 2025-01-30 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | レット症候群の治療におけるコレステロール ２４－ヒドロラーゼのための発現ベクター |
| AU2020367532A1 (en) | 2019-10-17 | 2022-05-12 | Ginkgo Bioworks, Inc. | Adeno-associated viral vectors for treatment of Niemann-Pick disease type C |
| WO2021113634A1 (en) * | 2019-12-05 | 2021-06-10 | The Board Of Regents Of The University Of Texas | Transgene cassettes designed to express a human mecp2 gene |
| EP4117735A4 (en) * | 2020-03-09 | 2024-04-10 | University of Massachusetts | Gene replacement therapy for foxg1 syndrome |
| US20230203102A1 (en) * | 2020-05-13 | 2023-06-29 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
| CN116322789A (zh) * | 2020-06-30 | 2023-06-23 | 爱丁堡大学理事会 | 转基因表达系统 |
| KR20230068444A (ko) | 2020-08-19 | 2023-05-17 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 레트 증후군의 치료를 위한 아데노 관련 바이러스 벡터 |
| CN112194706B (zh) * | 2020-09-30 | 2022-03-08 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
| WO2022094078A1 (en) * | 2020-10-28 | 2022-05-05 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of rett syndrome |
| MX2024004936A (es) | 2021-11-02 | 2024-05-08 | Voyager Therapeutics Inc | Variantes de capsides de aav y sus usos. |
| GB202201242D0 (en) * | 2022-01-31 | 2022-03-16 | Univ Edinburgh | Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders |
| CN121219020A (zh) * | 2023-03-22 | 2025-12-26 | 圣拉斐尔医院有限责任公司 | 基因疗法 |
| CN121175427A (zh) * | 2023-05-15 | 2025-12-19 | 上海金珂博生物技术有限公司 | 一种Rett综合症的基因治疗 |
| TW202513796A (zh) * | 2023-06-09 | 2025-04-01 | 大陸商仁景（蘇州）生物科技有限公司 | 表達可調控的工程化ｒｎａ分子及其用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| IL161827A0 (en) | 2001-11-13 | 2005-11-20 | Univ Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novelsequences identified thereby |
| US20040106566A1 (en) * | 2002-05-17 | 2004-06-03 | Shi-Lung Lin | RNA-splicing and processing-directed gene silencing and the relative applications thereof |
| CA2703329A1 (en) | 2007-10-23 | 2009-04-30 | Novartis Ag | Use of trkb antibodies for the treatment of respiratory disorders |
| CL2009000090A1 (es) | 2008-01-17 | 2009-07-24 | Irm Llc | Anticuerpo que se une al receptor de tirosina quinasa b (trkb); composicion que comprende el anticuerpo; metodo para reducir los niveles de glucosa en la sangre y/o el peso corporal en un individuo. |
| WO2010105096A2 (en) | 2009-03-11 | 2010-09-16 | University Of Massachusetts | Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212) |
| KR20140041387A (ko) | 2010-10-25 | 2014-04-04 | 엑스-마르세이유 위니베르시테 | ＭｅＣＰ2-관련 장애의 치료 |
| US20160000794A1 (en) | 2012-09-25 | 2016-01-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Methods for the diagnosis and treatment of sjogren's syndrome |
| WO2015038958A1 (en) | 2013-09-13 | 2015-03-19 | California Institute Of Technology | Selective recovery |
| US10072251B2 (en) | 2014-02-19 | 2018-09-11 | University Of Massachusetts | Recombinant AAVS having useful transcytosis properties |
| WO2015164786A1 (en) * | 2014-04-25 | 2015-10-29 | University Of Massachusetts | Recombinant aav vectors useful for reducing immunity against transgene products |
| US10711270B2 (en) | 2014-10-03 | 2020-07-14 | University Of Massachusetts | High efficiency library-identified AAV vectors |
| US10370432B2 (en) | 2014-10-03 | 2019-08-06 | University Of Massachusetts | Heterologous targeting peptide grafted AAVS |
| CN107073051B (zh) | 2014-10-21 | 2021-08-24 | 马萨诸塞大学 | 重组aav变体及其用途 |
| US11046955B2 (en) | 2015-04-24 | 2021-06-29 | University Of Massachusetts | Modified AAV constructs and uses thereof |
| EP3121284A1 (en) | 2015-07-22 | 2017-01-25 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Bicistronic aav vector for rna interference in als |
-
2018
- 2018-06-06 AU AU2018281145A patent/AU2018281145A1/en not_active Abandoned
- 2018-06-06 CA CA3066623A patent/CA3066623A1/en active Pending
- 2018-06-06 US US16/619,733 patent/US11680275B2/en active Active
- 2018-06-06 EP EP18812887.0A patent/EP3635122A4/en active Pending
- 2018-06-06 BR BR112019025732-2A patent/BR112019025732A2/pt not_active IP Right Cessation
- 2018-06-06 WO PCT/US2018/036200 patent/WO2018226785A1/en not_active Ceased
- 2018-06-06 SG SG11201911737PA patent/SG11201911737PA/en unknown
- 2018-06-06 KR KR1020207000120A patent/KR20200015701A/ko not_active Ceased
- 2018-06-06 JP JP2019567677A patent/JP2020522269A/ja active Pending
- 2018-06-06 CN CN201880051148.4A patent/CN111065742A/zh active Pending
- 2018-06-06 MX MX2019014760A patent/MX2019014760A/es unknown
- 2018-06-06 EA EA201992882A patent/EA201992882A1/ru unknown
-
2019
- 2019-12-04 IL IL271170A patent/IL271170A/en unknown
- 2019-12-06 CL CL2019003582A patent/CL2019003582A1/es unknown
- 2019-12-27 CO CONC2019/0014840A patent/CO2019014840A2/es unknown
-
2023
- 2023-05-03 US US18/311,367 patent/US20230416779A1/en active Pending
- 2023-08-23 JP JP2023135189A patent/JP2023164447A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023164447A (ja) | 2023-11-10 |
| BR112019025732A2 (pt) | 2020-06-30 |
| WO2018226785A1 (en) | 2018-12-13 |
| EA201992882A1 (ru) | 2020-05-25 |
| IL271170A (en) | 2020-01-30 |
| KR20200015701A (ko) | 2020-02-12 |
| CA3066623A1 (en) | 2019-12-13 |
| AU2018281145A1 (en) | 2020-01-02 |
| US11680275B2 (en) | 2023-06-20 |
| CO2019014840A2 (es) | 2020-01-17 |
| CN111065742A (zh) | 2020-04-24 |
| US20200181646A1 (en) | 2020-06-11 |
| EP3635122A1 (en) | 2020-04-15 |
| CL2019003582A1 (es) | 2020-09-25 |
| EP3635122A4 (en) | 2021-03-31 |
| JP2020522269A (ja) | 2020-07-30 |
| US20230416779A1 (en) | 2023-12-28 |
| SG11201911737PA (en) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019014760A (es) | Vectores de aav autoregulables para la expresión segura de mecp2 en el síndrome de rett. | |
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| SA520412637B1 (ar) | B7 الفيروس الغدي الحال للورم المشفِّر لبروتين | |
| PH12018502361A1 (en) | Gdf15 fusion proteins and uses thereof | |
| PH12017501436A1 (en) | Enhanced delivery of viral particles to the striatum and cortex | |
| MX2020006117A (es) | Integracion dirigida de acidos nucleicos. | |
| PH12018500594A1 (en) | Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same | |
| MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
| WO2015155686A3 (en) | Methods and compositions for rna-directed repression of transcription using crispr-associated genes | |
| MX2022012490A (es) | Vectores de aav para la terapia genica de la retina y el snc. | |
| EP3597760A3 (en) | Adeno-associated virus vector | |
| SG11201901306XA (en) | Artificially engineered angiogenesis regulatory system | |
| BR112015021884A8 (pt) | vetores de plasmídeo recombinantes, partícula viral avv ou pluralidade de partículas virais, seus métodos de produção e seus usos, e composição farmacêutica | |
| MX2019009316A (es) | Promotor corto y potente para la expresion de genes heterologos. | |
| MX2016014660A (es) | Medios y metodos para el tratamiento de cmv. | |
| AU2017256910A1 (en) | Optogenetic visual restoration using Chrimson | |
| MX2018003162A (es) | Variante en el numero de copias que genera resistencia a virus. | |
| PH12017501165B1 (en) | Dengue virus vaccine compositions and methods of use thereof | |
| EP4413990A3 (en) | Gene therapy for tuberous sclerosis | |
| MX2022004836A (es) | Vacunas mejoradas para la papilomatosis respiratoria recurrente y métodos para su uso. | |
| EA201991797A1 (ru) | Высокоактивный и короткий промотор, предназначенный для экспрессии гетерологичных генов | |
| MY185846A (en) | Oncolytic adenovirus encoding a b7 protein | |
| AR102679A1 (es) | Proteína recombinante; proceso de construcción de la misma y uso para el tratamiento de disturbios relacionados con la proliferación celular anómala | |
| TN2016000460A1 (en) | Aav vectors for retinal and cns gene therapy. |